Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rezurock
Pharma
J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD
Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease.
Kevin Dunleavy
Aug 25, 2022 9:37am
Kadmon adviser enriched himself during $1.9B Sanofi deal: SEC
May 25, 2022 10:45am
Rezurock shows link between organ responses and patient outcomes
Apr 21, 2022 8:57am
Acquisitive Sanofi buys GVHD drug via $1.9B takeover of Kadmon
Sep 8, 2021 8:16am
Kadmon gears up for its first-ever commercial drug launch
Jul 19, 2021 3:49pm
Kadmon's Rezurock scores surprise FDA nod
Jul 16, 2021 3:20pm
